News | January 18, 2023
Cipla launches Cippoint
Point-of-Care solution to facilitate clinicians in quick and effective decision making
Point-of-Care solution to facilitate clinicians in quick and effective decision making
Dr. Reddy’s will manufacture the Active Pharmaceutical Ingredient and finished drug at its facilities approved by USFDA
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
As per the agreement, NSE-listed Vaishali Pharma Limited will take over the entire domestic and international marketing of Jark Pharma’s portfolio of quality based ayurvedic products
EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
The investment will enable the company to enter European markets as well as enhance margins in current markets
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
The approval follows the positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in October 2022
The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas
Subscribe To Our Newsletter & Stay Updated
